DYRK1B

Across TCGA pan-cancer cohorts, DYRK1B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DYRK1B data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DYRK1B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DYRK1B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where DYRK1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.858	0.341	.006	14	view →
PDAC	DFS	Median	All	0.304	0.676	.016	12	view →
LUAD	DFS	Tertile	III,IV	0.732	0.352	.030	7	view →
GBM	OS	Quartile	All	0.592	0.324	.045	2	view →
LSCC	DFS	Quartile	II,III,IV	0.593	0.921	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DYRK1B–CCRCC (OS)

Open the CCRCC breakdown →